Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

Abstract Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy. Blood samples were obtained before and after immune checkpoint i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	So Yeon Oh, Soyeon Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/af1f07bdcb0141329418f0dc51069650
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:af1f07bdcb0141329418f0dc51069650
record_format	dspace
spelling	oai:doaj.org-article:af1f07bdcb0141329418f0dc510696502021-12-02T19:16:11ZSoluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment10.1038/s41598-021-99311-y2045-2322https://doaj.org/article/af1f07bdcb0141329418f0dc510696502021-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-99311-yhttps://doaj.org/toc/2045-2322Abstract Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy. Blood samples were obtained before and after immune checkpoint inhibitor therapy (January 2015 to January 2019). The study cohort consisted of 128 patients who were diagnosed with non-small cell lung cancer (n = 50), melanoma (n = 31), small cell lung cancer (n = 14), urothelial carcinoma (n = 13), and other cancers (n = 20). Patients with a high level (> 11.0 pg/μL) of sPD-L1 were more likely to exhibit progressive disease compared with those with a low level (41.8% versus 20.7%, p = 0.013). High sPD-L1 was also associated with worse prognosis; the median PFS was 2.9 (95% confidence interval [CI] 2.1–3.7) months versus 6.3 (95% CI 3.0–9.6) months (p = 0.023), and the median OS was 7.4 (95% CI 6.3–8.5) months versus 13.3 (95% CI 9.2–17.4) months (p = 0.005). In the multivariate analyses, high sPD-L1 was an independent prognostic factor for both decreased PFS (HR 1.928, p = 0.038) and OS (HR 1.788, p = 0.004). sPD-L1 levels did not correlate with tissue PD-L1 expression. However, sPD-L1 levels were positively correlated with neutrophil to lymphocyte ratios and negatively correlated with both the proportion and the total number of lymphocytes. We found that high pretreatment sPD-L1 levels were associated with progressive disease and were an independent prognostic factor predicting lower PFS and OS in these patients.So Yeon OhSoyeon KimBhumsuk KeamTae Min KimDong-Wan KimDae Seog HeoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q So Yeon Oh Soyeon Kim Bhumsuk Keam Tae Min Kim Dong-Wan Kim Dae Seog Heo Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
description	Abstract Circulating soluble programmed death-1 ligand (sPD-L1) is measurable in the serum of cancer patients. This study aimed to investigate the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy. Blood samples were obtained before and after immune checkpoint inhibitor therapy (January 2015 to January 2019). The study cohort consisted of 128 patients who were diagnosed with non-small cell lung cancer (n = 50), melanoma (n = 31), small cell lung cancer (n = 14), urothelial carcinoma (n = 13), and other cancers (n = 20). Patients with a high level (> 11.0 pg/μL) of sPD-L1 were more likely to exhibit progressive disease compared with those with a low level (41.8% versus 20.7%, p = 0.013). High sPD-L1 was also associated with worse prognosis; the median PFS was 2.9 (95% confidence interval [CI] 2.1–3.7) months versus 6.3 (95% CI 3.0–9.6) months (p = 0.023), and the median OS was 7.4 (95% CI 6.3–8.5) months versus 13.3 (95% CI 9.2–17.4) months (p = 0.005). In the multivariate analyses, high sPD-L1 was an independent prognostic factor for both decreased PFS (HR 1.928, p = 0.038) and OS (HR 1.788, p = 0.004). sPD-L1 levels did not correlate with tissue PD-L1 expression. However, sPD-L1 levels were positively correlated with neutrophil to lymphocyte ratios and negatively correlated with both the proportion and the total number of lymphocytes. We found that high pretreatment sPD-L1 levels were associated with progressive disease and were an independent prognostic factor predicting lower PFS and OS in these patients.
format	article
author	So Yeon Oh Soyeon Kim Bhumsuk Keam Tae Min Kim Dong-Wan Kim Dae Seog Heo
author_facet	So Yeon Oh Soyeon Kim Bhumsuk Keam Tae Min Kim Dong-Wan Kim Dae Seog Heo
author_sort	So Yeon Oh
title	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
title_short	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
title_full	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
title_fullStr	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
title_full_unstemmed	Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
title_sort	soluble pd-l1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/af1f07bdcb0141329418f0dc51069650
work_keys_str_mv	AT soyeonoh solublepdl1isapredictiveandprognosticbiomarkerinadvancedcancerpatientswhoreceiveimmunecheckpointblockadetreatment AT soyeonkim solublepdl1isapredictiveandprognosticbiomarkerinadvancedcancerpatientswhoreceiveimmunecheckpointblockadetreatment AT bhumsukkeam solublepdl1isapredictiveandprognosticbiomarkerinadvancedcancerpatientswhoreceiveimmunecheckpointblockadetreatment AT taeminkim solublepdl1isapredictiveandprognosticbiomarkerinadvancedcancerpatientswhoreceiveimmunecheckpointblockadetreatment AT dongwankim solublepdl1isapredictiveandprognosticbiomarkerinadvancedcancerpatientswhoreceiveimmunecheckpointblockadetreatment AT daeseogheo solublepdl1isapredictiveandprognosticbiomarkerinadvancedcancerpatientswhoreceiveimmunecheckpointblockadetreatment
_version_	1718376991633178624

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

Ejemplares similares